Commercial Manufacturing Of Lentiviral Vectors

Oxford Biomedica (OXB) is the first, and currently the only FDA – approved CDMO for the production of lentiviral vectors. We offer our partners the opportunity to leverage our extensive expertise and world-class manufacturing services and technologies to achieve successful commercialization of their lentiviral vector-based products.

OXB has extensive experience in the transfer of processes and products from other manufacturing sites or clients’ GMP facilities. We have invested heavily in process development and platform improvement, with a team of over 130 employees in this function, and are able to offer rapid tech transfer and implementation in our development labs.